Efficacy of abrocitinib monotherapy for the treatment of moderate-to-severe atopic dermatitis by race

被引：0

作者：

Alexis, A. F. ^{[1
]}

Silverberg, J. I. ^{[2
]}

Rice, Z. P. ^{[3
]}

Armstrong, A. W. ^{[4
]}

Desai, S. R. ^{[5
,6
]}

Fonacier, L. ^{[7
]}

Kabashima, K. ^{[8
]}

Levenberg, M. ^{[9
]}

Biswas, P. ^{[9
]}

Cella, R. Rojo ^{[10
]}

Chan, G. L. ^{[10
]}

机构：

[1] Weill Cornell Med Coll, New York, NY USA

[2] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA

[3] Dermatol Associates Georgia, Atlanta, GA USA

[4] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA

[5] Innovat Dermatol, Plano, TX USA

[6] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[7] NYU Langone Hosp Long Isl, Mineola, NY USA

[8] Kyoto Univ, Kyoto, Japan

[9] Pfizer Inc, New York, NY USA

[10] Pfizer Inc, Groton, CT 06340 USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 185卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

516

引用

页码：E137 / E138

页数：2

共 50 条

[41] A phase III study to investigate the efficacy and safety of abrocitinib and dupilumab in comparison with placebo in adults with moderate-to-severe atopic dermatitis [J].

Thaci, D. ;

Bieber, T. ;

Simpson, E. L. ;

Silverberg, J. I. ;

Paul, C. ;

Sinclair, R. ;

Pink, A. E. ;

Kataoka, Y. ;

Chu, C. -Y. ;

DiBonaventura, M. ;

Rojo, R. ;

Antinew, J. ;

Ionita, I. ;

Forman, S. ;

Zdybski, J. ;

Biswas, P. ;

Malhotra, B. ;

Zhang, F. ;

Valdez, H. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) :E72-E73

[42] Efficacy and safety of abrocitinib in biologic-exposed versus biologic-naive patients with moderate-to-severe atopic dermatitis [J].

Gooderham, M. ;

Strober, B. ;

Ardern-Jones, M. ;

Guttman-Yassky, E. ;

Levenberg, M. ;

Chan, G. ;

Biswas, P. ;

Watkins, M. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) :S53-S53

[43] Lebrikizumab for Moderate-to-Severe Atopic Dermatitis [J].

Smith, Brandon I. ;

Engel, Priya ;

Wu, Jashin .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24) :2299-2300

[44] Efficacy and safety of abrocitinib in adolescent patients with moderate-to-severe atopic dermatitis: stratified analysis across three clinical trials [J].

Simpson, E. ;

Lio, P. ;

Heath, C. ;

Boguniewicz, M. ;

Levenberg, M. ;

Biswas, P. ;

Farooqui, S. ;

Kerkmann, U. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) :E140-E140

[45] Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age [J].

Cork, Michael J. ;

Deleuran, Mette ;

Geng, Bob ;

Silverberg, Jonathan I. ;

Simpson, Eric L. ;

Gold, Linda F. Stein ;

Irvine, Alan D. ;

Romero, William ;

Valdez, Hernan ;

Fan, Haiyun ;

Alderfer, Justine .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2025, 13 (05) :1164-1175.e2

[46] Depth and rapidity of response with abrocitinib and dupilumab in patients with moderate-to-severe atopic dermatitis in JADE COMPARE [J].

Lio, P. ;

Boguniewicz, M. ;

Alexis, A. ;

Lebwohl, M. ;

Reich, K. ;

Pink, A. ;

Kabashima, K. ;

Bissonnette, R. ;

Nowicki, R. J. ;

Valdez, H. ;

Zhang, F. ;

DiBonaventura, M. ;

Clibborn, C. ;

Cameron, M. C. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) :E138-E139

[47] High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents [J].

Stander, S. ;

Bhatia, N. ;

Gooderham, M. J. ;

Silverberg, J., I ;

Thyssen, J. P. ;

Biswas, P. ;

DiBonaventura, M. ;

Romero, W. ;

Farooqui, S. A. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (08) :1308-1317

[48] Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis [J].

Nettis, Eustachio ;

Patella, Vincenzo ;

Lombardo, Carla ;

Detoraki, Aikaterini ;

Macchia, Luigi ;

Di Leo, Elisabetta ;

Carbonara, Monica ;

Canonica, Giorgio W. ;

Bonzano, Laura .

ALLERGY, 2020, 75 (10) :2653-2661

[49] Time to improvement in daily signs and symptoms associated with atopic dermatitis (AD) in patients with moderate-to-severe AD in pooled monotherapy studies of abrocitinib [J].

Gooderham, Melinda J. ;

Lebwohl, Mark G. ;

Simpson, Eric L. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) :AB120-AB120

[50] Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE [J].

Silverberg, Jonathan I. ;

Simpson, Eric L. ;

Pink, Andrew E. ;

Weidinger, Stephan ;

Chan, Gary ;

Biswas, Pinaki ;

Clibborn, Claire ;

Guler, Erman .

DERMATOLOGY AND THERAPY, 2025, 15 (02) :367-380

← 1 2 3 4 5 →